Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Core Insights - Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) fell by over 56% following the release of interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therapy [1] Company Summary - The significant drop in share price indicates a negative market reaction to the interim results of the clinical trial [1] - ARCT-032 is positioned as an inhaled mRNA therapy, which suggests a focus on innovative delivery methods in the biotechnology sector [1] Industry Context - The incident highlights the volatility and risks associated with clinical trial results in the biotechnology industry, particularly for companies developing novel therapies [1]